PTN

PALATIN TECH
AMEX

Real-time Quotes | Nasdaq Last Sale

0.5278
-0.0021
-0.40%
After Hours: 0.5277 -0.0001 -0.02% 17:51 07/10 EDT
OPEN
0.5300
PREV CLOSE
0.5299
HIGH
0.5357
LOW
0.5200
VOLUME
1.09M
TURNOVER
--
52 WEEK HIGH
1.133
52 WEEK LOW
0.3550
MARKET CAP
121.00M
P/E (TTM)
3.658
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTN stock price target is 2.167 with a high estimate of 3.000 and a low estimate of 1.500.

EPS

PTN News

More
Palatin resumes enrollment in mid-stage dry eye study
Seeking Alpha - Article · 2d ago
Palatin Technologies, Inc. Announces Reinitiation of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease
PR Newswire · 2d ago
Palatin Technologies, Inc. Announces Reinitiation Of Enrollment Of Phase 2 Study With PL9643 For Treatment Of Dry Eye Disease
CRANBURY, N.J., July 8, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the
Benzinga · 2d ago
Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders
PR Newswire · 06/29 12:30
Dow, S&P extend gains to second straight session, Nasdaq books fresh record close as Apple powers to new high
MarketWatch · 06/23 21:54
Dow, S&P extend gains to second straight session, Nasdaq books fresh record close as Apple powers to new high
marketwatch.com · 06/23 16:54
Coronavirus update: U.S. case tally surging with more than half the states trending up as death toll tops 120,000
marketwatch.com · 06/23 14:38
Palatin's stock rises on plans to test experimental drug as COVID-19 treatment
MarketWatch · 06/23 13:05

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About PTN

Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.
More

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.